Our group
An independent Group committed to therapeutic progress to serve patient needs.
35th
LARGEST PHARMACEUTICAL
GROUP WORLDWIDE
and 2nd largest pharmaceutical
Group in France*.
Over 130
COUNTRIES in which the
Group’s medicines are distributed
Over 20
THOUSAND EMPLOYEES worldwide
*IQVIA, Analytics Link / World 82 countries – MAT Q3-2025
Servier, a Global Pharmaceutical Group
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.
As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D.
Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.
Our vocation
We are committed to therapeutic progress to serve patient needs.
Our values
Care
Date to innovate
Grow by sharing
Commit to succeed
Our vision
Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world.
A comprehensive healthcare offering
Every day, Servier helps to treat patients in close to 140 countries using its extensive range of brand-name and generic medicines. In line with our conviction to offer a comprehensive range of health care solutions, we also provide e-health solutions that cover the entire patient journey.
Servier brand-name medicines
GENERIC MEDICINES
Research & Innovation
We have everything we need at our disposal to actively contribute to therapeutic progress, including a long-term vision, made possible by our unique governance model, an effective and collaborative approach to innovation, significant investment in R&D and a presence in the heart of global innovation communities.
We have chosen to focus our R&D efforts on therapeutic areas where medical needs remain considerable and are not yet tackled taking the increasingly targeted approach of precision medicine.
Servier research & development institute in Paris-Saclay
In Paris-Saclay, Servier will be able to develop a more agile and open approach to R&D that centers even more closely around the patient to speed up the discovery of innovative therapeutic solutions.
- 2023 opening in 2023
- 45,000sqm a building spanning
- 1,500 employees
More about Research & Innovation at Servier: https://servier.com/en/research-innovation/
Partnering with Servier
At Servier, partnering is at the heart of our innovation strategy with bold short-term objectives as part of our long-term ambition. We are a highly committed and experienced team focused on partnerships to further innovate for patients.
Partnering is a key enabler for our 2030 ambition and beyond: https://servier.com/en/partnering/
A Strong Industrial Network
At our 13 production sites located throughout the world, we produce and distribute our medicines to the highest standards on quality, safety, and reliability.
By harnessing digital innovation across the entire value chain, we continue to enhance our agility to meet patient demand.
Sustainability
Sustainability is rooted in our vocation as a pharmaceutical Group committed to therapeutic progress to serve patient needs. As a Group governed by a foundation, we naturally adopt a long-term perspective that shapes our decisions and actions. We maximize our health impact by serving Patients, People and the Planet.
Find out more: https://servier.com/en/our-commitments/
Mécénat Servier Charity Fund supports international initiatives in the fields of health, education, culture, living together and humanitarian aid. More information: https://mecenat.servier.com/